

## ihc-F SOX10 Ab Anti-Human SOX10 (Clone R1008)

Ab: KF32040-005 and KF32040-015, 50 and 150 tissue stains\*  
Ab-Enh: KF49040-### (005, -010, -015, -030) 50, 100, 150, or 300 tissue stains\*. \* Estimated at 100µL per tissue volume.

### Intended Use: For In Vitro Diagnostic Use

Novodiox ihc anti-SOX10 (Sry-related HMG-Box gene 10, Clone R1008) is a rabbit monoclonal antibody intended for laboratory use to qualitatively identify by light microscopy the presence of SOX10 in sections of frozen cryostat tissues using immunohistochemistry (IHC) test methods. The interpretation of any staining or its absence should be complemented by morphological studies using proper controls. These reagents have been pre-diluted and optimized for IHC when used together without further dilution.

### Summary and Explanation:

ihc-F SOX10 is a monoclonal rabbit primary antibody that is paired with the polymerized HRP in ihc Enhancer, a Moure-Rabbit antibody amplifying reagent for IHC use on frozen tissues. SOX10 is also called SRY-related HMG-box 10 protein, which is the transcription factor known to be crucial in the specification of the neural crest and maintenance of Schwann cells and melanocytes. It is expressed in nuclei of melanocytes, peripheral nerve sheath cells, and breast myoepithelial cells. Positive nuclear staining for SOX10 is seen in breast basal-like, unclassified triple negative, and metastatic carcinoma. SOX10 also shows an increased specificity for soft tissue tumors of neural crest origin compared with S100. SOX10 along with other markers like MITF1 may be useful in differentiating melanoma in situ from actinic keratosis with melanocytic hyperplasia. Adding ihc Enhancer following the application of SOX10 antibody creates staining signal. A chromogen such as 3,3'-diaminobenzidine (DAB) is then used to develop color at the reaction site.

### Principle of Procedure:

The ready-to-use (RTU) ihc-F SOX10 antibody reagent is directly applied to pretreated tissue sections, where it binds to SOX10 antigens in tissue. Following antibody incubation, tissues are washed and a signal amplifier (ihc Enhancer) is applied. The tissues are washed again and a Working Solution (WS) of a chromogen such as ihc DAB 1:1 is applied. Polymerized HRP (pHRP) reacts with the chromogen to form a visible colored product at the site of SOX10 binding location. The specimen can be counterstained and a coverslip applied. Results are viewed and interpreted using a light microscope. Volumes are based upon 100µl antibody per tissue. This product may be used manually or on an automated IHC staining system.

### Reagents Provided:

Part No.	Σ	Description
KF32040-005	50	5ml size ihc SOX10 RTU antibody.
KF32040-015	150	15mL of ihc SOX10 RTU antibody
KF49040-005	50	5ml size of ihc SOX10 RTU antibody plus, 5mL size of ihc Enhancer K51011-005.
KF49040-010	100	2x5mL size of ihc SOX10 RTU antibody plus, 2x5mL size of ihc Enhancer K51011-005.
KF49040-015	150	15ml size of ihc SOX10 RTU antibody plus, 15mL size of ihc Enhancer K51011-015
KF49040-030	300	2x15ml size ihc SOX10 RTU antibody plus, 2X15ml size of ihc Enhancer K51011-005.

Above volumes are estimated at 100µl of ihc antibody/ihc Enhancer per tissue

Immunogen	Clone	Species	Ig Class	Total Protein Conc.
Recombinant SOX10	R1008	Rabbit	IgG1	<8 mg/ml

SOX10 antibody is a rabbit monoclonal antibody purified from ascites. HRP is extracted from horseradish plant. The ihc Enhancer is a signal amplification reagent that is necessary for the reaction. Novodiox ihc DAB 1:1 Kit or ihc Magenta 1:1 t are recommended for use with the SOX10 antibody.

[www.novodiox.com](http://www.novodiox.com)  
[Sales@novodiox.com](mailto:Sales@novodiox.com)  
[Support@novodiox.com](mailto:Support@novodiox.com)

IFU-00177-EN-A SOX10 ihc-F June 2025

### SOX10 Ab Components (KF32040-###):

Reagent Description	Component Part Numbers	Sizes (ml)
ihc SOX10	H32040-Q### (005, 015)	5, 15

### SOX10 Ab-Enh Components (K49040-###, items may be shipped separately):

Reagent Description	Component Part Numbers	Sizes (ml)
ihc SOX10	H32040-Q### (005, 015)	5, 15
ihc Enhancer	D28020-R### (005, 015)	5, 15

### Ancillary Reagents for Use with SOX10 Antibody:

Reagent Description	Part Numbers	Sizes (ml)
ihc Blocker (Intl.)	K50001-### (015)	15
ihc Blocker (USA)	K50002-### (015, 030)	15, 30
ihc Enhancer (required)	K51011-### (015, 030)	15, 30
ihc DAB 1:1 Kit	K50002-### (015, 030)	15, 30
ihc Magenta 1:1 Kit	K50011-### (015, 030)	15, 30

### Materials Needed but Not Provided:

The following reagents/supplies may be required in staining but are not provided:

1. Frozen section fixative (10% NBF§ **recommended**)
  2. Positive and negative control tissues
  3. Microscope slides, positively charged (**recommended**)
  4. Staining jars, baths or processing tools
  5. ihc Wash Buffer (PBS-T)
  6. Pipettor and pipet tips
  7. Timer
  8. Antigen retrieval buffer (when using FFPE tissues)
  9. Peroxide blocker (optional)
  10. Instruments used for tissue pretreatment, such as water bath, or pressure cooker or microwave oven (when using FFPE tissues)
  11. Hematoxylin
  12. Xylene or Xylene substitute
  13. Ethanol
  14. Mounting medium
  15. Cover slips
  16. Light microscope (40 - 400x)
- § NBF – neutral buffered formalin

### Novodiox Bulk Reagent Formulations:

ihc Wash Buffer (PBS-T), (10 mM phosphate buffer, pH7.2, 150 mM NaCl, 0.05% Tween-20). Dilute 10X ihc Wash Buffer in DI water until 1X.

### Storage and Handling:

This product should be stored at 2-8°C and is suitable for use until expiration date when stored at this temperature. Do not freeze. Do not use the product after expiration date unless dating extension information is provided by Novodiox. If reagents are stored under any conditions other than those specified in the package insert, they must be validated by the user.

**Frozen Tissue Sections:** Frozen tissue is sectioned to the appropriate thickness (approximately 4 µm) and placed on a positively charged glass slide. Tissues should be fixed in reagent grade 10% NBF for 1-2 minutes immediately after sectioning. Reagent grade NBF may be kept cold, e.g. cryostat temperatures, or room temperature. Following fixation, tissues should be processed within a few minutes or may be stored in PBS for several hours.

**Treatment of Tissues Prior to Staining:** Pretreatment is tissue dependent and should be performed as suggested in the staining procedure sections.

### Warnings and Precautions:

1. Read and understand all of the Novodiox Instructions for Use (IFUs) before product use.
2. Neutral buffered formalin (NBF) is preferred over acetone for a frozen tissue fixative.
3. The ready-to-use ihc SOX10 antibody and ihc Enhancer signal amplification reagents are pre-diluted. Further dilution may reduce signal intensity or increase



Novodiox, Inc.  
3517 Breakwater Ave  
Hayward, CA 94545, USA  
Phone: +1 (888) 439-2716

the possibility of false-negative staining. These recommendations are for guidance only. Laboratory managers should determine their own procedures and quality policies.

- To obtain best results when working with frozen tissues, it is desirable to freeze tissues as quickly as possible following extraction.
- Use caution and shorten incubation times when utilizing intense hematoxylin counterstains such as Gills as these stains may tend to mask antibody staining.
- Take reasonable precautions when handling reagents. Use protective equipment such as disposable gloves and lab coats when handling materials. Read Safety Data Sheets (SDS) prior to use.
- Avoid contact of reagents with eyes and mucous membranes. If reagents come in contact with sensitive areas, wash with copious amounts of water.
- Use charged slides to secure tissue adhesion and a level lab surface for testing.
- Patient specimens and all materials that come into contact with patient specimens should be handled as bio-hazardous materials and disposed of appropriately.
- Consult local or state authorities with regard to recommended method of disposal of bio-hazardous and hazardous chemical waste materials.
- Incubation time and temperature other than those specified may give erroneous results. The user must validate any such changes.
- Use lab grade quality chemicals such as NBF and water when preparing reagents. Users should validate performance including stability for laboratory prepared reagents (at 1x).
- Avoid microbial contamination of reagents.
- Fixation is a vital part of the protocol and fixation times may vary with the fixative chosen, tissue type, e.g. containing fat and other parameters. Generally, an acetone or NBF fixation of 1-2 minutes is recommended. Place frozen tissue sections into fixation solution shortly after sectioning. **Prolonged exposure to room or freezing temperatures may alter targeted epitopes.**
- It is best to prevent slides from drying out during the staining process to avoid unwanted background staining

#### General Operating Notes: SOX10

- Equilibrate all reagents to room temperature prior to use. Swirl or shake the ihc Enhancer and labeled antibody solutions before use. **Do not vortex.** Calculate the amount of chromogen WS needed (100µl per tissue) and **freshly** prepare chromogen WS. See instructions for use.
- Gently and thoroughly wash tissues during manual wash steps. Avoid direct high velocity streams of wash that might tend to damage or cut delicate tissues.
- Following each manual assay step, remove excess fluids on tissue slides with tissue paper. Excessive residual solution may dilute subsequent reagents, causing negative or uneven staining. Users may also utilize a PAP pen to ensure reagents stay on the desired tissues.
- To reduce background signal, wash thoroughly following antibody and enhancer step.
- For the tissues with high oxidase activity, blocking with H<sub>2</sub>O<sub>2</sub> may be required to minimize non-specific staining.
- The following protocol has been validated at temperatures between 21°-30°C (70°-86°F) for incubating SOX10 antibody, and ihc Enhancer and a Novodiox chromogen working solution (WS). If room temperature is less than 21°C, users may need to incubate labeled antibody for a longer period of time (≤5 minutes) to achieve satisfactory staining results. Consistent results have been obtained at room temperature or using a slide warmer set to 30°C at the surface of the slide.

#### Staining Procedures:

##### Performing IHC on Frozen Tissue Sections:

- Following **fixation in NBF**, rinse slides with 1x ihc Wash buffer and then wipe away any excess fluid with a Kimwipe® or paper towel.
- Optional: apply sufficient ihc Blocker, (est. 100µL) to cover the entire tissue and incubate for 1 minute. After 1 minute, do not wash, but wipe around tissue and remove excess fluid.
- Dispense enough antibody, (est. 100µL) to cover the entire tissue, and incubate for 3 minutes at room temperature. If room temperatures are below 21°C or if darker staining is desired, extend incubation times to obtain desired stain intensities. Thoroughly rinse slides with 1x ihc Wash buffer.
- Before the next step, wipe away any excess fluid and dispense enough ihc Enhancer to cover the entire tissue and incubate for 3 minutes.
- Next, thoroughly rinse slides with 1x ihc Wash buffer and then wipe away any excess fluid per the above instructions.
- Dispense sufficient chromogen WS e.g. DAB to cover the entire tissue, and incubate for ~3 minutes. Users should determine the optimal incubation time for their particular chromogen and lab environment. Then rinse slides with either 1x ihc Wash buffer or lab grade water and wipe away any excess fluid.

- Add a counterstain. Incubation times will vary according to the counterstain formulation. Then, rinse slides with water and wipe away any excess fluid.
- Apply aqueous media or dehydrate slides following the established dehydration and permanent mounting media protocols, then add coverslip.

#### Test Timing Est. (12-15 minutes IHC protocol for frozen tissue sections):

ihc-F SOX10 Antibody+Enhancer Frozen Tissue Procedure	Time in minutes
Fix with Neutral Buffered Formalin	1-2
- Wash with ihc Wash Buffer, remove excess fluid	- - -
<i>*Optional: Block with ihc Blocker</i>	1-2
- Tap+Absorb fluid to remove excess blocker	- - -
Novodiox ihc Antibody reagent	3
- Wash thoroughly with ihc Wash Buffer	- - -
- Tap+Absorb to remove excess wash buffer	- - -
ihc Enhancer amplifier	3
- Wash thoroughly with ihc Wash Buffer	- - -
- Tap+Absorb to remove excess wash buffer	- - -
Chromogen Working Solution (DAB / Magenta)	3 / 3
- Wash with ihc Wash Buffer or DI water	- - -
Hematoxylin counterstain (Intensity Dependent)	2-45 sec
Wash with water	- - -
Dehydrate/Mounting Medium and Coverslip	User Det.
<b>Total</b>	<b>~12-15</b>

#### Quality Control Procedures:

Positive and negative controls should be run simultaneously with patient specimens.

**Positive Tissue Control:** The recommended positive control tissues for this antibody are properly processed melanoma and skin. The staining is nuclear for melanoma cells and melanocytes in skin. One positive tissue control for each set of test conditions should be included in each staining run. Previous tissue specimens that have been frozen and freshly cut or in some cases, an individual's own tissue may be used as controls.

The tissues used for the positive control should be selected from patient specimens with characterized positive target activity that gives positive staining. Known positive tissue controls should only be utilized for monitoring the correct performance of processed tissues and test reagents, rather than as an aid in formulating a specific diagnosis of patient samples. If the positive tissue controls fail to demonstrate positive staining, results with the patient specimens should be considered invalid.

**Negative Tissue Control:** The same tissue used for the positive control may be used as the negative tissue control. The variety of cell types in most tissue sections offers internal negative control sites. But this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining (false positive staining) occurs in the negative tissue control sites, results with the patient specimens must be considered invalid. Breast carcinoma and lung carcinoma tissues may be used as negative tissue control.

#### Troubleshooting:

If an unexpected staining pattern occurs on control tissues or patient samples, consider the following:

- No staining:** If no staining is evident on positive control slide, please verify whether (1) chromogen WS was prepared freshly and correctly, (2) reagents were applied in the correct order, (3) that antibody was indeed added, and (4) for FFPE tissue, dewaxing and antigen retrieval were performed adequately. Perform any corrective actions required and then repeat the procedure.













2. *Low signal or faint staining:* Please check whether (1) the reagents are not expired, (2) temperature of the testing environment was at least 21°C or a 30°C slide warmer was used, (3) chromogen WS was prepared freshly and correctly, (4) excess ihc Wash solution was not left on the slide, causing subsequent reagents to be diluted, and (5) for FFPE tissue, dewaxing and antigen retrieval were performed adequately. Perform any required corrective actions and repeat the procedure. Alternatively, if using a DAB chromogen, consider using another stain, e.g. ihc Magenta 1:1 to obtain more vibrant staining. In addition, some individuals may naturally have low expression of certain antigens. In these cases, users may extend the antibody incubation times by 1-2 minutes.
3. *High background:* Possible causes include (1) insufficient washing, (2) specimens drying out, (3) prolonged chromogen incubation, (4) prolonged antibody or Enhancer incubation, and (5) specimens containing high level of endogenous peroxidase, which necessitates an additional blocking step (refer to the Staining Procedures for Paraffin Tissues). Perform any required corrective actions and repeat the procedure.

If an unexpected staining pattern is observed on control tissues or patient samples which cannot be explained by variations in laboratory procedures or a problem with the antibody is suspected, contact Novodiox Technical Support or your local distributor immediately. Within the US and Canada call 1 (888) 439-2716 ext. 2 or 1 (510) 342-3043 ext. 2.

#### Expected Results:

Intense color stains the tissue with a clean background if SOX10-expressed cells exist. There will be no color staining if no SOX10-expression cells exist in the tissue. Interpretation of the staining result is solely the responsibility of the user.

ihc-F SOX10 Key to Symbols			
	In vitro diagnostic medical device		SOX10 antibody reagent
	Catalog Number		pHRP Mouse/Rabbit amplification reagent
	Use by: YYYY-MM-DD		Manufacturer
	Consult Instruction for Use		Contains sufficient for < n > tests
	Batch Code		Temperature Limitations

#### General Limitations:

Immunohistochemistry is a multistep diagnostic process that requires specialized training in the selection of the appropriate reagents; tissue selection, fixation, and processing; preparation of the IHC slide; and interpretation of the staining results. Improper fixation, freezing, thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, antibody trapping, or false negative results. Inconsistent results may be due to variations in fixation and embedding methods, or to inherent irregularities within the tissue (Nadji M, Morales AR. 1983).

The manufacturer provides these antibodies/reagents at optimal dilution for use following the provided instructions for IHC on prepared tissue sections. Any deviation from recommended test procedures may invalidate declared expected results; appropriate controls must be employed and documented. Users who deviate from recommended test procedures must accept responsibility for interpretation of patient results under these circumstances.

#### Performance Characteristics:

The ihc-F SOX10 test performance has been determined using both frozen and FFPE tissue sections. Novodiox has conducted studies to evaluate the performance and the accompanying reagents and ancillary supplies. The antibodies and systems have been found to be sensitive and show specific binding to the antigen of interest with minimal to no binding of non-specific tissues or cells. Novodiox antibodies and accompanying reagents have shown reproducible and consistent results when used within a single run, between runs and between lots. These products have been determined to be stable for the periods of time specified on the labels either by standard real-time and/or accelerated methods. Novodiox ensures product quality by testing each lot of material and by testing materials at regular intervals and via surveillance programs.

#### Instructions for Use (IFU) Access:

To obtain a translation or the latest electronic version of an IFU document, visit our website at <https://www.novodiox.com/literature/instructions-for-use-ifu/>. Printed copies of an IFU document may be obtained by contacting Novodiox Technical Support or your local distributor.

#### Bibliography:

1. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
2. Sheehan DC and Hrapchak BB. Theory and Practice of Histotechnology. St. Louis: C.V.Mosby Co. 1980.
3. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med, 1983; 14: 767-771.
4. Miettinen M et al. Sox10 – A marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue. A systematic analysis of 5134 tumors. Am J Surg Pathol. 2015 June; 39(6) 826-835.
5. Buonaccorsi JN et al. Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases. Am J Dermatopathol. 2014 Feb; 36(2): 124-30.
6. Kang Y et al. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol. 2014 Jan; 27(1): 55-61.

